On this episode of Not So Different, we reminisce about the major biosimilar news to come out of the rheumatology field during January 2023, including the launch of the first Humira (adalimumab) biosimilar.
On this episode of Not So Different, we reminisced about the major biosimilar news to come out of the rheumatology field during January 2023, including the launch of the first Humira (adalimumab) biosimilar.
Show notes
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Canada Approves High-Concentration Humira Biosimilar
https://www.centerforbiosimilars.com/view/canada-approves-high-concentration-humira-biosimilar
Celltrion Submits BLA for Infliximab Biobetter
https://www.centerforbiosimilars.com/view/celltrion-submits-bla-for-infliximab-biobetter
FDA Accepts BLA for Alvotech Ustekinumab Biosimilar
https://www.centerforbiosimilars.com/view/fda-accepts-bla-for-alvotech-ustekinumab-biosimilar
Biosimilars Check-in: Approval in Saudi Arabia, Launch in Republic of Korea, Dr. Reddy’s Completes Study
China's NMPA Approves Tocilizumab Biosimilar
https://www.centerforbiosimilars.com/view/china-s-nmpa-approves-tocilizumab-biosimilar
US Welcomes First Adalimumab Biosimilar, Amjevita
https://www.centerforbiosimilars.com/view/us-welcomes-first-adalimumab-biosimilar-amjevita
Study: Does Adalimumab Lose Effectiveness After Switching to a Biosimilar?
Phase 1 Trial for Alvotech Golimumab Biosimilar Begins
https://www.centerforbiosimilars.com/view/phase-1-trial-for-alvotech-golimumab-biosimilar-begins
Case Study: Treatment With Adalimumab Biosimilar Resolved Pediatric Scalp, Nail Psoriasis
Phase 3 Study Reports Similar Efficacy Between SB17, Stelara in Psoriasis
October 19th 2024A phase 3, 28-week comparative clinical trial in patients with moderate to severe plaque psoriasis confirmed similarity of the proposed ustekinumab biosimilar SB17 (Samsung Bioepis) to the reference product (Stelara) in efficacy, safety, pharmacokinetics, and immunogenicity.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.